Wadiha Freije is a notable inventor based in Forest Park, IL (US). He has made significant contributions to the field of cancer evaluation through his innovative methods and technologies. With a total of 4 patents, Freije has established himself as a key figure in the development of diagnostic tools for cancer.

Latest Patents

Freije's latest patents include groundbreaking methods for evaluating the methylation status of a polynucleotide. This invention provides methods related to assessing the methylation status that includes an internal control. Another significant patent focuses on materials and methods for assaying the methylation of CpG islands associated with genes in the evaluation of cancer. This patent outlines methods, reagents, and kits for evaluating various cancers, such as prostate cancer, in a subject. The disclosed methods include diagnosing cancer, prognosticating cancer, and assessing the efficacy of cancer treatment. These methods involve assaying a biological sample for methylation of a CpG island associated with specified genes, and the provided reagents and kits include primers suitable for amplifying portions of target CpG islands.

Career Highlights

Freije is currently associated with Euclid Diagnostics LLC, where he continues to innovate in the field of cancer diagnostics. His work has been instrumental in advancing the understanding and evaluation of cancer through methylation analysis.

Collaborations

Freije collaborates with talented individuals such as Igor Brikun and Deborah Nusskern, contributing to a dynamic research environment focused on cancer evaluation technologies.

Conclusion

Wadiha Freije's contributions to cancer evaluation through his innovative patents and collaborative efforts highlight his importance in the field. His work continues to pave the way for advancements in cancer diagnostics and treatment methodologies.